Clinical Trials Logo

AFib clinical trials

View clinical trials related to AFib.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06335498 Completed - Atrial Fibrillation Clinical Trials

Further Study of AFGen1 Clinical Performance

CS3
Start date: April 2, 2024
Phase:
Study type: Observational

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish further evidence for the clinical performance of AFGen1 on human participants.

NCT ID: NCT06076798 Completed - Atrial Fibrillation Clinical Trials

Clinical Performance of AFGen1

Start date: October 5, 2023
Phase:
Study type: Observational

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of AFGen1 on human participants.

NCT ID: NCT05295056 Completed - Atrial Fibrillation Clinical Trials

Clinical Performance of the AFGen1 Device Over a 7-day Period

Start date: May 12, 2022
Phase:
Study type: Observational

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of the AFib-Chek device (a.k.a. Device) on human participants.

NCT ID: NCT01997905 Completed - Atrial Fibrillation Clinical Trials

Stroke Feasibility Study

Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage. The purpose is for evaluation of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation who are unable to take Oral Anticoagulants.